Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line NSCLC Treatment

Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line NSCLC Treatment is organized by Healthcare Made Practical (HMP) Communications LLC and will be Nov 21, 2018 - Nov 21, 2019.

Intended Learners:
This activity is designed for directors of oncology practice programs and cancer centres, oncologists, haematologists, commercial and government payers, pathway development executives, reimbursement specialists, speciality pharmacists, HEOR specialists, and other healthcare professionals interested in learning how to implement, integrate, and measure treatment pathways.

Accreditation:
CME: Naccme Designates This Enduring Material For A Maximum Of 0.75 Ama Pra Category 1 Credits™. Physicians Should Claim Only The Credit Commensurate With The Extent Of Their Participation In The Activity.

Physician Assistants: Naccme Has Been Authorized By The American Academy Of Pas (Aapa) To Award Aapa Category 1 CME Credit For Activities Planned In Accordance With The Aapa Cme Criteria. This Activity Is Designated For 0.75 Aapa Category 1 Credit(S). Pas Should Only Claim Credit Commensurate With The Extent Of Their Participation In The Activity.

CNE: This Continuing Nursing Education Activity Awards 0.75 Contact Hours. Provider Approved By The California Board Of Registered Nursing, Provider #13255 For 1.50 Contact Hours.

Nursing Pharmacology Hours: This Continuing Nursing Educational Activity Awards Up To 0.75 Pharmacology Hours.

Learning Objectives:
After Completing This Activity, Participants Should Be Able To:
• Outline the clinical and socioeconomic consequences of care variations and suboptimal guideline adherence in the first-line treatment of advanced NSCLC
• Describe the impact of genetic mutations and genomic heterogeneity on therapeutic selection and pathway design for NSCLC
• Integrate the efficacy and safety, indications, and cost-utility of available EGFR tyrosine kinase inhibitors (TKIs) and monoclonal antibodies into optimal first-line selection and NSCLC pathway placement strategies.